Could a once-a-day pill replace weight loss injections? Phase II oral GLP-1 drug trial shows promising results

Article excerpt

Researchers testing Elecoglipron, an oral GLP-1 drug taken once daily, report promising Phase II trial results that could offer weight-loss benefits without injections. The small-molecule compound targets the same receptor as popular injectable medications like Ozempic and Wegovy, but in pill form. For patients who fear needles or struggle with injection logistics, oral delivery could significantly expand access to GLP-1 therapy. The trial data suggests the once-a-day formulation achieves comparable weight-loss effects to existing treatments. Elecoglipron represents one of several pharmaceutical efforts to make GLP-1 drugs more convenient and patient-friendly as demand for weight-management medications continues to surge.